China Health Group Past Earnings Performance
Past criteria checks 0/6
China Health Group's earnings have been declining at an average annual rate of -37.5%, while the Life Sciences industry saw earnings growing at 24.7% annually. Revenues have been declining at an average rate of 20.8% per year.
Key information
-37.5%
Earnings growth rate
-37.6%
EPS growth rate
Life Sciences Industry Growth | 41.4% |
Revenue growth rate | -20.8% |
Return on equity | -69.1% |
Net Margin | -270.8% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Does China Health Group (HKG:8225) Deserve A Spot On Your Watchlist?
Jan 28Should You Be Adding China Health Group (HKG:8225) To Your Watchlist Today?
Apr 14Announcing: China Health Group (HKG:8225) Stock Increased An Energizing 170% In The Last Five Years
Mar 09Is China Health Group Inc.'s (HKG:8225) Latest Stock Performance A Reflection Of Its Financial Health?
Feb 10Does China Health Group (HKG:8225) Deserve A Spot On Your Watchlist?
Jan 14If You Had Bought China Health Group (HKG:8225) Stock A Year Ago, You Could Pocket A 546% Gain Today
Nov 26Revenue & Expenses BreakdownBeta
How China Health Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 21 | -58 | 66 | 0 |
30 Sep 23 | 18 | -10 | 21 | 0 |
30 Jun 23 | -2 | -26 | 21 | 0 |
31 Mar 23 | 3 | -22 | 22 | 0 |
31 Dec 22 | 13 | -16 | 22 | 0 |
30 Sep 22 | 41 | 11 | 20 | 0 |
30 Jun 22 | 46 | 13 | 21 | 0 |
31 Mar 22 | 72 | 30 | 26 | 0 |
31 Dec 21 | 84 | 36 | 28 | 0 |
30 Sep 21 | 87 | 54 | 13 | 0 |
30 Jun 21 | 89 | 62 | 15 | 0 |
31 Mar 21 | 88 | 63 | 12 | 0 |
31 Dec 20 | 83 | 61 | 12 | 0 |
30 Sep 20 | 75 | 46 | 21 | 0 |
30 Jun 20 | 74 | 34 | 21 | 0 |
31 Mar 20 | 68 | 31 | 21 | 0 |
31 Dec 19 | 63 | 28 | 21 | 0 |
30 Sep 19 | 61 | 23 | 25 | 0 |
30 Jun 19 | 60 | 24 | 25 | 0 |
31 Mar 19 | 61 | 24 | 25 | 0 |
31 Dec 18 | 60 | 23 | 25 | 0 |
30 Sep 18 | 69 | 35 | 24 | 0 |
30 Jun 18 | 74 | 41 | 23 | 0 |
31 Mar 18 | 65 | 34 | 22 | 0 |
31 Dec 17 | 58 | 30 | 23 | 0 |
30 Sep 17 | 30 | 10 | 13 | 0 |
30 Jun 17 | 21 | 2 | 15 | 0 |
31 Mar 17 | 22 | 3 | 14 | 0 |
31 Dec 16 | 20 | 2 | 14 | 0 |
30 Sep 16 | 32 | -2 | 21 | 0 |
30 Jun 16 | 32 | 0 | 19 | 0 |
31 Mar 16 | 27 | -1 | 17 | 0 |
31 Dec 15 | 21 | -3 | 14 | 0 |
30 Sep 15 | 7 | 53 | 9 | 0 |
30 Jun 15 | 7 | 48 | 11 | 0 |
31 Mar 15 | 4 | 45 | 12 | 0 |
31 Dec 14 | 6 | 44 | 13 | 0 |
30 Sep 14 | 9 | -32 | 20 | 0 |
30 Jun 14 | 8 | -30 | 18 | 0 |
31 Mar 14 | 8 | -34 | 19 | 0 |
31 Dec 13 | 15 | -31 | 21 | 0 |
30 Sep 13 | 19 | -5 | 19 | 0 |
30 Jun 13 | 24 | -2 | 19 | 0 |
Quality Earnings: 8225 is currently unprofitable.
Growing Profit Margin: 8225 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 8225 is unprofitable, and losses have increased over the past 5 years at a rate of 37.5% per year.
Accelerating Growth: Unable to compare 8225's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 8225 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (2.8%).
Return on Equity
High ROE: 8225 has a negative Return on Equity (-69.15%), as it is currently unprofitable.